Gerd Binnig, PhD, founded Definiens AG in 2000 after an extended pre-development phase. He is IBM fellow and honorary professor at the Ludwig– Maximilian University of Munich (LMU), Germany, and has received many prizes as a major pioneer in nanotechnology, including the Nobel Prize (1986) and the Kavli Prize (2016). With Definiens, he enabled computers to include context in cognitive processes.
Ralf Huss is an adjunct professor of pathology and managing director of the Institute of Pathology and Molecular Diagnostics, University Hospital Augsburg (Germany), where he also chairs the Institute for Digital Medicine. Dr. Huss is board certified in anatomical, experimental, and molecular pathology with more than 30 years of training and experience in histopathology, immunology, translational cancer research, and oncology in Zurich (Switzerland), Seattle (USA), and Munich (Germany). Dr. Huss has also held different senior positions in the pharmaceutical industry at Roche and AstraZeneca. He also serves as an honorary professor at the University College Dublin (Ireland) and as a lecturer of nanotechnology and biomaterials at the Faculty of Chemistry, Technical University of Munich (Germany). His research interest is mainly on the use of machine and artificial intelligence in routine tissue diagnostics and biomarker discovery, and he has (co-)authored more than 150 peer-reviewed articles, reviews, book chapters, and books in related areas.
Guenther Schmidt, PhD, heads the scientific research team at Definiens. He has been contributing to the tissue phenomics methodology with his expertise in image analysis, data mining, and systems biology. He is author of numerous publications and holds several patents related to tissue phenomics.
